Nature Medicine, Published online: 15 July 2026; doi:10.1038/d41591-026-00035-1
Positive results from several trials with ex vivo gene editing suggest that reactivating fetal hemoglobin in sickle cell disease and β-thalassemia is now a reliable therapeutic strategy after years of uncertainty.
